Vaccine safety issues at the turn of the 21st century

Laura Conklin,1 Anders Hviid,2 Walter A Orenstein,3 Andrew J Pollard,4,5 Melinda Wharton,6 Patrick Zuber 7

ABSTRACT

Global gains in vaccination coverage during the early 21st century have been threatened by the emergence of antivaccination groups that have questioned the effectiveness of vaccines to generate public distrust of vaccines and immunisation programmes. This manuscript summarises six key topics that have been at the centre of global discussions on vaccine safety during the early 21st century: thiomersal in multi-dose non-live vaccines, aluminium adjuvants used with several non-live vaccines, autism and auto-immune conditions as possible consequences of vaccination, a risk of immune overload with increasing numbers of vaccinations, and detrimental non-specific effects (NSEs) of vaccination. For each topic, we describe the hypothesis behind the public concern, the evidence reviewed by the WHO’s Global Advisory Committee for Vaccine Safety (GACVS) during 1999–2019, and any significant new data that has emerged since GACVS conclusions were made. Although the scientific evidence on these issues overwhelmingly supports the safety of vaccines, communication messages to caregivers and providers need to condense and convey scientific information in an appropriate way to address concerns contributing to vaccine distrust. In addition, there is need for further studies specifically designed to address both positive and negative NSEs of vaccination. The role of GACVS will be increasingly important in evaluating the evidence and engaging the global community in promoting safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.

INTRODUCTION

Due to advances in modern medicine, the global community now benefits from greatly reduced rates of serious infectious diseases that used to be common. Immunisation is the largest clearly documented contributor to this progress, and vaccines may also play an increasingly important role in controlling the spread of antibiotic-resistant and antiviral-resistant organisms.1 Nevertheless, sustaining the gains in global vaccination programmes requires maintaining public trust in both vaccine efficacy and vaccine safety. Misinformation on vaccinations, their ingredients and their mechanisms of action, is now easily perpetuated through social media and misinformed public figures. Numerous vaccine safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.

Since 1999, the GACVS has reviewed the evidence on different vaccine components (eg, thiomersal in multi-dose non-live vaccines, aluminium adjuvants used with several non-live vaccines, autism and auto-immune conditions as possible consequences of vaccination, a risk of immune overload with increasing numbers of vaccinations, and detrimental non-specific effects (NSEs) of vaccination). For each topic, we describe the hypothesis behind the public concern, the evidence reviewed by the WHO’s Global Advisory Committee for Vaccine Safety (GACVS) during 1999–2019, and any significant new data that has emerged since GACVS conclusions were made. Although the scientific evidence on these issues overwhelmingly supports the safety of vaccines, communication messages to caregivers and providers need to condense and convey scientific information in an appropriate way to address concerns contributing to vaccine distrust. In addition, there is need for further studies specifically designed to address both positive and negative NSEs of vaccination. The role of GACVS will be increasingly important in evaluating the evidence and engaging the global community in promoting safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.

Since 1999, the GACVS has reviewed the evidence on different vaccine components (eg, thiomersal in multi-dose non-live vaccines, aluminium adjuvants used with several non-live vaccines, autism and auto-immune conditions as possible consequences of vaccination, a risk of immune overload with increasing numbers of vaccinations, and detrimental non-specific effects (NSEs) of vaccination). For each topic, we describe the hypothesis behind the public concern, the evidence reviewed by the WHO’s Global Advisory Committee for Vaccine Safety (GACVS) during 1999–2019, and any significant new data that has emerged since GACVS conclusions were made. Although the scientific evidence on these issues overwhelmingly supports the safety of vaccines, communication messages to caregivers and providers need to condense and convey scientific information in an appropriate way to address concerns contributing to vaccine distrust. In addition, there is need for further studies specifically designed to address both positive and negative NSEs of vaccination. The role of GACVS will be increasingly important in evaluating the evidence and engaging the global community in promoting safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.

Since 1999, the GACVS has reviewed the evidence on different vaccine components (eg, thiomersal in multi-dose non-live vaccines, aluminium adjuvants used with several non-live vaccines, autism and auto-immune conditions as possible consequences of vaccination, a risk of immune overload with increasing numbers of vaccinations, and detrimental non-specific effects (NSEs) of vaccination). For each topic, we describe the hypothesis behind the public concern, the evidence reviewed by the WHO’s Global Advisory Committee for Vaccine Safety (GACVS) during 1999–2019, and any significant new data that has emerged since GACVS conclusions were made. Although the scientific evidence on these issues overwhelmingly supports the safety of vaccines, communication messages to caregivers and providers need to condense and convey scientific information in an appropriate way to address concerns contributing to vaccine distrust. In addition, there is need for further studies specifically designed to address both positive and negative NSEs of vaccination. The role of GACVS will be increasingly important in evaluating the evidence and engaging the global community in promoting safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.

Since 1999, the GACVS has reviewed the evidence on different vaccine components (eg, thiomersal in multi-dose non-live vaccines, aluminium adjuvants used with several non-live vaccines, autism and auto-immune conditions as possible consequences of vaccination, a risk of immune overload with increasing numbers of vaccinations, and detrimental non-specific effects (NSEs) of vaccination). For each topic, we describe the hypothesis behind the public concern, the evidence reviewed by the WHO’s Global Advisory Committee for Vaccine Safety (GACVS) during 1999–2019, and any significant new data that has emerged since GACVS conclusions were made. Although the scientific evidence on these issues overwhelmingly supports the safety of vaccines, communication messages to caregivers and providers need to condense and convey scientific information in an appropriate way to address concerns contributing to vaccine distrust. In addition, there is need for further studies specifically designed to address both positive and negative NSEs of vaccination. The role of GACVS will be increasingly important in evaluating the evidence and engaging the global community in promoting safety concerns have drawn much public attention over the last several decades and were reviewed in detail during the early years of the Global Advisory Committee for Vaccine Safety (GACVS), an advisory committee established by the WHO in 1999 to provide independent, scientifically rigorous advice on vaccine safety issues of potential global importance. The GACVS terms of reference includes the transparent review of the latest scientific data, in all fields ranging from basic sciences to epidemiology, concerning any aspect of vaccine safety of global or regional interest. Reports from committee meetings are available to the public on the internet on the GACVS website https://www.who.int/vaccine_safety/committee/reports/en/. GACVS may revisit a given safety topic multiple times when new or otherwise relevant information becomes available.
vaccines and aluminium adjuvants used in several non-live vaccines) multiple times, as well as any association between vaccination and broad categories of adverse health outcomes, including autism, overloading the immune system, a possible association between vaccines and auto-immune syndromes, and increased mortality among vaccine recipients as possible non-specific effects (NSEs) of immunisation. Each of these issues has been linked to reduced public trust in vaccines and vaccination programmes. Therefore, a robust body of scientific evidence has been generated in the last several decades to assess the biological and epidemiological plausibility of these safety concerns and assure the safety of vaccinations worldwide.

In this manuscript, we summarise the GACVS review of these topics, the conclusions and recommendations that were made, any recent data for the Committee’s consideration, and the implications for future work on these topics.

**ALUMINIUM ADJUVANTS**

Aluminium is ubiquitous in the environment and is a component of many consumer products, including antacids, astringents and antiperspirants. Since the early 20th century, aluminium has been used as an adjuvant to enhance immune responses to vaccines in a variety of forms including aluminium oxide, hydroxide and soluble salts. The mechanism of action is complex and includes direct stimulation of multiple immune receptors, thereby enhancing the body’s natural immune response to the antigen. Concentrations of aluminium vary greatly among different vaccine products, primarily non-live vaccines, ranging from none in measles, mumps, rubella (MMR) vaccine to 1.5 mg of aluminium phosphate per dose in diphtheria-tetanus (DT) vaccine.

While daily aluminium exposure in humans can range from 0.06 mg/day (from inhaling particulates in the air) to 3500–5200 mg/day (from antacid consumption), aluminium has been associated with encephalopathy in high intravenous exposures, such as those received through renal dialysis or intravenous nutritional products. These data have been used by organised groups who are opposed to vaccination to hypothesise a link between the immunisations and developmental delays and other adverse neurological outcomes. More recently, aluminium adjuvants have been alleged to cause poorly defined autoimmune syndromes.

Multiple high-quality studies have shown that children who receive vaccines containing aluminium adjuvants do not have aluminium in their blood or hair above the minimum risk levels established by the Agency for Toxic Substances and Disease Registry, and they are not at increased risk of adverse neurodevelopmental outcomes. The GACVS reviewed the available safety data on adjuvants, including aluminium compounds for the first time in 1999, specifically addressing a type of histopathological lesion of unknown origin called macrocytic myofasciitis (table 1). In 2004, the Committee recognised the need for surveillance of vaccine adjuvant safety, particularly in low-income and middle-income countries, and made recommendations for WHO to consider developing a website for adjuvant contents of vaccines. In addition, the Committee asserted that the role of GACVS and WHO regarding adjuvant safety was to review and consolidate the evidence. After reviewing several studies in 2012 alleging an association between aluminium and autism spectrum disorders, the GACVS emphasised that ecological studies should not be used to assess a causal association because these types of studies are unable to link exposure outcomes to individuals.

### Table 1: Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on aluminium adjuvants

| GACVS report | Exposure | Outcome | Report link |
|--------------|----------|---------|-------------|
| 1999 September | Aluminium | MMF | https://www.who.int/vaccine_safety/committee/reports/wer7441.pdf?ua=1 |
| 2002 June | Aluminium | MMF | https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1 |
| 2003 December | Aluminium | MMF | https://www.who.int/vaccine_safety/committee/reports/wer7903.pdf?ua=1 |
| 2004 June | Adjuvants (general) | General safety | https://www.who.int/vaccine_safety/committee/reports/wer7929.pdf?ua=1 |
| 2004 December | Adjuvants (general) | General safety | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8001.pdf?ua=1 |
| 2005 December | Adjuvants (general) | General safety | https://www.who.int/vaccine_safety/committee/reports/wer8102.pdf?ua=1 |
| 2012 June | Aluminium | Autism Pharmaco-kinetics | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1 |

MMF, macrocytic myofasciitis.
During the same meeting in 2012, the Committee also reviewed a pharmacokinetic model of aluminium-containing vaccines from the US Food and Drug Administration. Results from this quantitative risk assessment showed that the body burden of aluminium following the injections of aluminium-containing vaccines never exceeds the safe US regulatory thresholds based on orally ingested aluminium, even for low birthweight infants.

Although the evidence on the safety of aluminium adjuvants is strongly reassuring, the public concern continues to be fueled by poorly designed studies and inaccurate extrapolation from such studies. As new vaccines and adjuvants are developed, continued safety monitoring is important during both prelicensure and postlicensure to ensure safety of the vaccine, address public concerns and maintain trust.

**THIOMERSAL**

Thiomersal is best known as a vaccine preservative, primarily used in multidose vials of non-live vaccines for its antiseptic and antifungal properties. Thiomersal is metabolised into ethylmercury, an organic mercury compound, and is used in concentrations corresponding to 12.5–50 µg of ethylmercury per vaccine dose. Concerns about the cumulative exposure of mercury from childhood vaccination schedules and other sources led to the replacement of thiomersal-containing vaccines with thiomersal-free formulations in many high-income countries in the 1990s and early 2000s. For example, the estimated exposure to ethylmercury from vaccines in the US childhood immunisation schedule in 1999 was 237.5 µg (275 µg if three doses of influenza vaccine were also administered) by 2 years of age. While mercury compounds are all neurotoxic at sufficiently large doses, most of the concern about thiomersal-containing vaccines were based on experiences with methylmercury—a different organic mercury compound with known neurotoxic effects. Humans primarily encounter methylmercury through fish consumption, and there is ample evidence that fetal exposure, especially through fish consumption in pregnancy has adverse effects on neurodevelopment. However, ethylmercury has different pharmacokinetic properties than methylmercury. The half-life of ethyl mercury is short (less than 1 week) compared with methyl mercury (1.5 months), making exposure to ethyl mercury in blood comparatively brief. Moreover, it is excreted rapidly via the gastrointestinal tract.

Large studies from Denmark, the UK, and the USA during 2003–2010, comparing more than 690 000 children have evaluated the association between thiomersal-containing vaccines and autism; they have all reached the same conclusion: there is no evidence that thiomersal-containing vaccines increase the risk of autism. Similarly, studies looking at a wide range of neurodevelopmental outcomes, including both diagnostic outcomes and early life behaviour, cognition and motor skills have been reassuring. The most notable study was conducted in the USA with the prospective enrolment of 1047 children at the ages of 7–10 years, assessing 42 neuropsychological outcomes. Thiomersal exposure was determined retrospectively from medical records and included exposure from immunisations, immunoglobulins and prenatal exposure during pregnancy. Overall, the results did not support an association between thiomersal and increased risk of neuropsychological outcomes. A few associations, both positive and negative, were noted, consistent with what would be expected due to chance when conducting a large number of statistical tests.

GACVS has reviewed the thiomersal issue multiple times from 2002 to 2012 (table 2), including comprehensive

| GACVS report | Exposure | Outcome | Report link |
|--------------|----------|---------|-------------|
| 2002 June    | DTP, HepB | Neurodevelopmental delay, Leukaemia | https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1 |
| 2003 June    | HepB, other | General safety | https://www.who.int/vaccine_safety/committee/reports/wer7832.pdf?ua=1 |
| 2004 Dec     | Thiomersal (animal models) | Autism, neurodevelopmental delay | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8001.pdf?ua=1 |
| 2005 June    | Thiomersal | Mercury levels | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8028.pdf?ua=1 |
| 2008 June    | HepB, Thiomersal | Mercury levels, Neuropsychological performance | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8332.pdf?ua=1 |
| 2012 June    | Thiomersal | Mercury levels, autism, neurodevelopmental delay, special risk groups | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1 |

DTP, diphtheria, tetanus and pertussis vaccine; HepB, hepatitis B vaccine.
reviews of both pharmacokinetic studies on ethylmercury and epidemiological studies of neurodevelopmental outcomes. The Committee concluded that thiomersal-containing vaccines do not increase the risk of autism or the risk of many other neurodevelopmental outcomes.13

Thiomersal has a proven history of efficacy and safety. While thiomersal has been removed from the routinely used paediatric vaccines in most high-income countries as a precautionary measure, as an effective preservative it continues to play a vital role as a preservative in allowing access to uncontaminated vaccines for millions of people globally. It is also noteworthy, that in countries where thiomersal has been removed from childhood vaccines, the prevalence of neurodevelopmental disorders such as autism has continued to increase.

AUTISM

The hypothesised link between vaccines and autism continues to cause concern and fear among parents despite many large, well-conducted studies showing that administration of vaccines is not associated with increased risk of autism.26–36 An increasing body of evidence supports that autism is a predominantly genetic disorder with an inheritance of up to 80%.26 The concept of a vaccine-autism link originally gained mainstream attention in the wake of a later retracted *Lancet* paper from 1998, suggesting an association between the MMR vaccine and autism.27 At the beginning of the 2000s, the mercury-containing vaccine preservative thiomersal was also linked to autism via claimed neurotoxic effects, as discussed earlier.26 More recently, aluminium adjuvants and expanding routine immunisation schedules have been postulated to cause autism via neurotoxicity and immune overload, respectively.5 29 Many anecdotal observations of autistic signs, developing shortly after or even immediately after vaccination, and a supposed autism epidemic coinciding with expanding immunisation schedules have been the two common arguments raised by the proponents of the link between vaccination and autism. First, it must be recognised that the natural onset of autism symptoms coincides with the scheduled vaccinations at certain ages; hence, purely by chance, some parents will observe early autistic signs after vaccinations. Second, the notion of an autism epidemic is disputed. The main reasons contributing to the increased reporting of autism diagnoses in many countries are the increased recognition of the condition—including the less debilitating manifestations on the autistic spectrum—and the fact that a diagnosis is often needed for government help and support.30

The Committee reviewed the issue of MMR vaccination and autism in late 2002 and concluded that there was no evidence to support a link.31 During the period of 2002–2012, the Committee reviewed several times the issue of thiomersal and neurodevelopmental disorders, including autism and reached the same conclusion: there was no support for a link between thiomersal and autism13 (table 3).

The strongest evidence against the postulated links between vaccination and autism comes from large, well-controlled epidemiological studies, including several key studies originating from Denmark. In 2002, Danish researchers reported a nationwide cohort study of more than 537,303 children with individual-level information on MMR vaccination and autism diagnoses.32 In this large cohort, there was no significant difference in the rate of autism between the group of children who received the MMR vaccine and those who did not. A similar nationwide study in 2003 compared 467,450 Danish children vaccinated with either a thiomersal-containing pertussis

### Table 3: Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on autism

| GACVS report | Exposure | Outcome | Report link |
|--------------|----------|---------|-------------|
| 2002 June    | DTP      | Neurodevelopmental delay | https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1 |
| 2002 December | Multiple | Autism            | https://www.who.int/vaccine_safety/committee/reports/wer7804.pdf?ua=1 |
| 2004 December | Multiple | Autism, neurodevelopmental delay | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8001.pdf?ua=1 |
| 2012 June    | Aluminium | Autism         | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1 |
| 2012 June    | Thiomersal | Mercury levels, autism, neurodevelopmental delay, special high-risk groups (eg, premature infants, immunocompromised infants) | https://www.who.int/vaccine_safety/committee/topics/thiomersal/wer8730.pdf?ua=1 |

DTP, diphtheria, tetanus and pertussis vaccine.
vaccine or a thiomersal-free formulation of the same pertussis vaccine. There was no association between thimerosal content and autism. The Danish researchers revisited the MMR–autism issue in 2019. In a new cohort of 657,461 children not included in the two previous studies; they found no association between MMR vaccination and autism. Other notable studies include case-control studies from the UK and the USA on MMR vaccination and autism and cohort studies on thimerosal and autism, also from the UK and the USA. A 2014 meta-analysis confirmed that vaccines do not increase the risk of autism. A common response to the many well-conducted observational studies reporting no association has been the claims of vulnerable subgroups of children or specific vaccine-induced phenotypes of autism. These claims are also not supported by observational research.

AUTO-IMMUNITY

Auto-immune diseases include a wide variety of different pathologies that are often poorly defined. Associations between vaccination and chronic auto-immune conditions (eg, multiple sclerosis, thyroid disease and autoimmune encephalitis) are largely based on the concept of molecular mimicry whereby auto-antibodies are produced after exposure to an infectious agent. This phenomenon has been linked to some natural infections, including Group A Streptococcus (rheumatic fever) and measles virus (acute disseminated encephalomyelitis).

The postulated link between vaccination and auto-immune conditions has been extensively explored via controlled trials, observational studies and epidemiological analyses in multiple countries and in subpopulations. For the hepatitis B vaccine, the lack of an association with rheumatoid arthritis, thyroid disease or multiple sclerosis has been clearly proven. In the case of the human papillomavirus vaccine (HPV), there is strong evidence against an elevated risk of Guillian-Barré syndrome (GBS), central demyelinating disease and multiple sclerosis. Current evidence does suggest a small elevated risk of GBS after influenza vaccination although these data are limited, and the risk is considerably lower than the risk of GBS after natural influenza infection. During the 2009/2010 influenza pandemic, there was also the evidence of a causal relationship between narcolepsy and one adjuvanted H1N1 vaccine among school-aged children who had a genetic predisposition. Nevertheless, investigators concluded that natural viral infection may have played a role in this observation as a vaccine-enhanced viral immunopathology rather than an isolated vaccine-induced autoimmune event.

The Committee has reviewed data on the possible relationship between autoimmune conditions and a variety of different vaccines over the years (2002–2017) (table 4); however, the safety profile of HPV remained a major focus from 2009 to 2017 due to ongoing public concerns fuelled by antivaccination groups. In 2009, GACVS concluded that there was no convincing evidence of an association between HPV vaccination and central demyelinating diseases. In 2013, the Committee reviewed evidence from the USA, Australia, Japan, France, and the manufacturers of Cervarix (GlaxoSmithKline) and Gardasil (Merck) in regard to autoimmune diseases with a focus on multiple sclerosis. They concluded that the studies demonstrated no increased risk of autoimmune diseases, including multiple sclerosis, among girls who received the HPV vaccine compared with those who did not.

The topic of autoimmunity was again revisited in 2015 when GACVS reviewed data from a retrospective cohort study in France, involving over 2 million girls, which showed a similar incidence of autoimmune conditions in the vaccinated and unvaccinated populations for all conditions studied, with the exception of GBS where increased risk was identified, mainly focused within 3 months after vaccination. The risk in the first few months after vaccination was very small (~1 per 100,000 vaccinated children) and had not been seen in other smaller studies. The Committee concluded that additional studies with adequately sized populations would help evaluate this finding. In July 2017, safety data for >3 million women aged 18–44 years from Denmark and Sweden were reviewed, and it showed an apparent increased risk of coeliac disease after HPV vaccination. The Committee and study investigators agreed that this most likely represented an unmasking of an existing condition during the vaccination visit rather than a causal association and that overall, the study did not raise any other autoimmune safety issues of concern. The Committee expressed concern that, despite accumulated safety evidence, including several million persons comparing the risks for a wide range of health outcomes in HPV-vaccinated and unvaccinated subjects, public attention continued to focus on spurious case reports and unsubstantiated allegations. In 2019, the Committee released a communication about the safety of HPV vaccines to address the rumours and misinformation.

The temporal association of the autoimmune disease with vaccination is not sufficient to support a causal relationship, and the global evidence supports that vaccines do not increase the risk of auto-immune diseases. One of the challenges associated with continuous safety monitoring data is that temporal but not causal relationships will be observed, which could pose further challenges for communication when taken in haste, out of context, and in the absence of the overall body of evidence.

IMMUNE OVERLOAD

The number of antigens recommended by WHO’s Expanded Programme on Immunisation to be delivered in routine immunisation schedules during infancy has increased over the past few generations from 6 in 1974 to 12 antigens in 2019. The concept of immune system ‘overload’ from many vaccinations is poorly defined but generally refers to the belief that the body has either a reduced response to multiple antigens given at the same

Conklin L, et al. BMJ Global Health 2021;6:e004898. doi:10.1136/bmjgh-2020-004898
time or that an individual is more vulnerable to other infections after vaccination due to an immune system weakened by response to multiple vaccine antigens.

Multiple studies have assessed the immune response to different vaccines and vaccine combinations, whether administered concomitantly or as multi-component vaccines.57–61 Randomised controlled trials and epidemiological studies of MMR vaccine have shown similar immunological responses, whether given singly or in combination with other vaccines, and no increased risk of invasive bacterial infection up to 90 days after immunisation was found.57 58 Similarly, MMR has been shown to have no interference with responses to other vaccines given concomitantly.59 60 Nevertheless, some studies have shown that other combination vaccines reduce immunological responses due to individual components.60 61 For example, in one randomised trial of coadministration of DT-acellular pertussis (DTaP) and haemophilus influenzae type B vaccine (Hib) conjugate vaccines at 4 and 6 months of age, a difference in Hib antibody concentrations was observed in groups receiving Hib capsular polysaccharide mixed with diphtheria, tetanus and pertussis vaccine (DTP) when compared with groups receiving the vaccines separately.60

Still, it is estimated that infants have the theoretical capacity to respond to about 10 000 vaccines at any given time and that only 0.1% of the immune system would be ‘used up’ if 11 vaccines were administered at one time.62 Despite this, parental concerns about immune system overload have persisted and resulted in delayed or

| GACVS report | Exposure | Outcome | Report link |
|--------------|----------|---------|-------------|
| 2002 June    | HepB     | Multiple sclerosis, Bell’s palsy | [link](https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1) |
| 2003 December | Influenza | GBS, multiple sclerosis, optic neuritis | [link](https://www.who.int/vaccine_safety/committee/reports/wer7903.pdf?ua=1) |
| 2005 December | HepB     | Chronic fatigue | [link](https://www.who.int/vaccine_safety/committee/reports/wer8102.pdf?ua=1) |
| 2006 November | Meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8203.pdf?ua=1) |
| 2007 June    | Meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8228_29.pdf?ua=1) |
| 2007 December | Influenza, DTP, tetanus, meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8304.pdf?ua=1) |
| 2008 December | HPV      | Central demyelinating disease, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer8405.pdf?ua=1) |
| 2013 June    | HPV      | GBS, allergic reaction | [link](https://www.who.int/vaccine_safety/committee/reports/wer8829.pdf?ua=1) |
| 2013 December | HPV      | Multiple sclerosis, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer8907.pdf?ua=1) |
| 2015 December | HPV      | GBS, POTS, CRPS, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer9103.pdf?ua=1) |
| 2016 December | Influenza (H1N1) | Narcolepsy | [link](https://apps.who.int/iris/bitstream/handle/10665/253062/WER9202.pdf?sequence=1) |
| 2017 June    | HPV      | GBS, POTS, CRPS, other | [link](https://www.who.int/vaccine_safety/committee/reports/June_2017/en/) |

CRPS, complex regional pain syndrome; DTP, diphtheria, tetanus and pertussis vaccine; GBS, Guillain-Barré syndrome; HepB, hepatitis B vaccine; HPV, human papillomavirus vaccine; POTS, postural orthostatic tachycardia syndrome.

---

**Table 4** Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on auto-immune and related conditions

| GACVS report | Exposure | Outcome | Report link |
|--------------|----------|---------|-------------|
| 2002 June    | HepB     | Multiple sclerosis, Bell’s palsy | [link](https://www.who.int/vaccine_safety/committee/reports/wer7747.pdf?ua=1) |
| 2003 December | Influenza | GBS, multiple sclerosis, optic neuritis | [link](https://www.who.int/vaccine_safety/committee/reports/wer7903.pdf?ua=1) |
| 2005 December | HepB     | Chronic fatigue | [link](https://www.who.int/vaccine_safety/committee/reports/wer8102.pdf?ua=1) |
| 2006 November | Meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8203.pdf?ua=1) |
| 2007 June    | Meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8228_29.pdf?ua=1) |
| 2007 December | Influenza, DTP, tetanus, meningococcal | GBS | [link](https://www.who.int/vaccine_safety/committee/reports/wer8304.pdf?ua=1) |
| 2008 December | HPV      | Central demyelinating disease, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer8405.pdf?ua=1) |
| 2013 June    | HPV      | GBS, allergic reaction | [link](https://www.who.int/vaccine_safety/committee/reports/wer8829.pdf?ua=1) |
| 2013 December | HPV      | Multiple sclerosis, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer8907.pdf?ua=1) |
| 2015 December | HPV      | GBS, POTS, CRPS, other | [link](https://www.who.int/vaccine_safety/committee/reports/wer9103.pdf?ua=1) |
| 2016 December | Influenza (H1N1) | Narcolepsy | [link](https://apps.who.int/iris/bitstream/handle/10665/253062/WER9202.pdf?sequence=1) |
| 2017 June    | HPV      | GBS, POTS, CRPS, other | [link](https://www.who.int/vaccine_safety/committee/reports/June_2017/en/) |

CRPS, complex regional pain syndrome; DTP, diphtheria, tetanus and pertussis vaccine; GBS, Guillain-Barré syndrome; HepB, hepatitis B vaccine; HPV, human papillomavirus vaccine; POTS, postural orthostatic tachycardia syndrome.
alternative dosing schedules, particularly in high-income countries. A survey of US paediatricians in 2016 revealed that 73% encountered parental requests for delaying of vaccines because of concerns about immune system overload, despite the strong evidence on the immune system’s ability to handle multiple vaccinations, either in combination or when administered simultaneously.

GACVS reviewed the evidence on immune overload in June 2006 and discussed the influence of vaccination schedules on the protective responses that may be induced, as well as the effect of factors such as malnutrition or exposure to environmental pathogens that may differ in various country settings (table 5). It concluded that the available evidence did not support the hypothesis that vaccines weaken or harm the immune system but emphasised that additional epidemiological studies, assessing the presence of an association between vaccination and recurrent infant infections or atopic dermatitis would be welcome and would reinforce the confidence of both healthcare providers and the public in infant immunisation programmes. Since that time, a large body of new evidence has accrued on this topic underscoring that the number of vaccines or vaccine antigens does not increase the risk for other infections or other conditions.64-66

### NON-SPECIFIC EFFECTS

NSEs of vaccines, whereby vaccination induces protection from or susceptibility to infections not targeted by the vaccine, remains a polarising topic. While there is some support for the existence of NSEs, there is little consensus on if and how these translate into clinically meaningful effects and if they should inform public health policies.67 The best evidence indicates that certain vaccines might have beneficial effects, reducing all-cause mortality.68 However, the claim that certain inactivated vaccines increase mortality is of the greatest concern. In 2000, it was reported that the DT-whole cell pertussis (DTwP) vaccine increased mortality among children in Guinea-Bissau.69 Among children followed during infancy, receiving at least one dose of DTwP increased mortality by 72% compared with children without DTwP vaccinations although it was concluded that the DTwP effect was complicated by the concomitant administration of the oral polio vaccine. Since 2000, several observational studies on NSEs from low-income countries have been published, many of them from Guinea-Bissau. An ambitious systematic meta-analysis attempted to summarise all available evidence on NSEs and childhood mortality in 2016.70 The authors reported a statistically non-significant increase in all-cause mortality of 38% associated with DTwP vaccination (almost always administered together with oral polio) based on 10 studies all classified as being at ‘high risk’ of bias. Proponents of the hypothesis that DTwP is detrimental claim that common sources of bias does not skew towards an increase in risk, and that the true effect of DTwP on mortality may be even greater than reported.71 However, as a recent simulation study demonstrates, scenarios where DTwP If has no causal effect on mortality but is observed to be associated with increased mortality, do exist when right-censoring occurs, for example, at the time of measles vaccination, as has been the case for some of the studies on DTwP.72 Prior DTwP increases the probability of measles vaccination and better health (lower mortality risk) increases the probability of measles vaccination, then conditioning on measles vaccination by right-censoring introduces selection bias in the observed association between DTwP and mortality in the form of increased risk. This suggests that caution is warranted when attempting to predict the influence of bias in these studies. The observations between DTwP and mortality cannot be evaluated in high-income countries. DT-acellular pertussis (aP) vaccine is predominantly used and infant mortality is low. A number of studies have attempted to evaluate the effect of DTaP and other inactivated vaccines on off-target infectious disease hospitalisation (IDH).73-78 A group of Danish researchers has reported that (1) receiving a third dose of a DTaP vaccine as the last vaccine was associated with increased risk of IDH compared with receiving MMR as the last vaccine in a small cohort of children not vaccinated according to the recommended schedule and (2) receiving MMR together with a third dose of DTaP increased the risk of being hospitalised with lower respiratory infections compared with receiving MMR alone.73 74 A US study evaluated live vaccines compared with inactivated vaccines as the latest vaccine given and observed a reduced risk of IDH, following a live vaccine compared with an inactivated vaccine.75 These results are in contrast to another Danish study which did not report any increased risks of IDH after different inactivated vaccines including whole-cell pertussis vaccine, a Dutch study reporting a protective effect on IDH of receiving a fourth DTaP vaccine compared with three, and a self-controlled case series study from England reporting no increased risk of IDH for children receiving MMR.

| GACVS report | Exposure | Outcome | Link |
|--------------|---------|---------|------|
| 2006 June    | Multiple (MMR, DTaP, Hib, other) | antibody concentrations, disease outcomes | https://www.who.int/vaccine_safety/committee/reports/wer8128.pdf?ua=1 |

DTaP, diphtheria, tetanus-acellular pertussis; Hib, haemophilus influenzae type B vaccine; MMR, measles, mumps and rubella vaccine.

Table 5 Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on immune overload.
vaccine together with an inactivated vaccine compared with children receiving MMR alone. 76–78 In a rare study of mortality following vaccination in a high-income country, Danish researchers reported reduced mortality for more doses of the DTaP vaccine received compared with fewer.79

The GACVS, the WHO Strategic Advisory Group of Experts on Immunisation and dedicated global Task Forces have reviewed the evidence on NSEs80–82 (table 6). The conclusions have consistently been and remain that the evidence on NSEs is not sufficient to warrant changes in global immunisation policy.81 82 Claims of DTwP increasing childhood mortality are not based on biological mechanisms and have not been shown to be scientifically reproducible. Therefore, further studies specifically designed to address both positive and negative NSEs are needed, especially given the well-established beneficial effects of DTwP vaccines.

CONCLUSIONS
During the 20th century, global immunisation efforts have seen unprecedented gains. An estimated 116.5 million children completed a 3-dose series of DTP-containing vaccine in 2016 alone compared with only 24.2 million in 1980.83 This progress has been accompanied by an abundance of data on the safety of immunisations and their components, although sometimes with conflicting results. As an independent scientific advisory board, the GACVS has played an essential role in critically reviewing the available body of evidence on vaccine safety issues of potential global importance and making recommendations to ensure that public trust in vaccinations is maintained.

The issues that have been central to the discussions on vaccine safety in the 21st century highlight the importance of robust scientific studies from multiple disciplines to make adequate conclusions on the safety of each vaccine at a global level. This includes both prelicensure and postlicensure safety assessments and surveillance data from multiple sources and epidemiological settings. The new Global Vaccine Safety Blueprint V.2.0 emphasises the role of adequate country safety surveillance systems; however, only 64% of the countries met the WHO’s minimum criteria for a functional system in 2015.84 Even when such data are available, their interpretation may be complex and has the potential for ambiguity that may contribute to vaccine distrust. Communication messages regarding vaccine safety need to incorporate subtle science to effectively address public concerns. With new vaccines under development and the potential for additional antigens to be added to the routine schedule in the next decade, explanations about dosing schedules and basic immune system function are particularly important to reduce fears and encourage timely dosing. This includes the translation of GACVS decisions into tools and other resources to help healthcare providers communicate effectively with caregivers when the data clearly support or disprove the safety of immunisation, as well as when the data are less clear regarding a specific outcome of public concern. The WHO has been working with global partners to establish global resources, such as the Vaccine Safety Net (https://www.who.int/vaccine_safety/initiative/communication/network/vaccine_safety_websites/en/), that promote effective communication strategies, bolster community confidence and allay public concerns when they arise.

Although some of the data presented here have come to light since GACVS last convened for a formal review, they further support the committee’s conclusions. As we move into an era of new vaccination platforms, antigens and formulations, the role of GACVS will be increasingly important in decoding the evidence and engaging the global community in promoting and assuring the safety of vaccines in the decades to come.

Table 6 Global Advisory Committee for Vaccine Safety (GACVS) reports released during 1999–2019 that included review of data on non-specific effects (NSEs) of vaccines

| GACVS report   | Exposure | Outcome                  | Link                                                                 |
|----------------|----------|--------------------------|----------------------------------------------------------------------|
| 2002 June      | DTP      | NSE, child mortality     | https://www.who.int/vaccine_safetycommittee/reports/ker7747.pdf?ua=1 |
| 2003 December  | DTP, BCG | NSE, child mortality     | https://www.who.int/vaccine_safetycommittee/reports/ker7903.pdf?ua=1 |
| 2004 June      | DTP      | NSE, child mortality     | https://www.who.int/vaccine_safetycommittee/reports/ker7929.pdf?ua=1 |
| 2008 June      | DTP      | NSE, child mortality     | https://www.who.int/vaccine_safetycommittee/reports/ker8332.pdf?ua=1 |

BCG, bacille Calmette-Guérin vaccine; DTP, diphtheria, tetanus and acellular pertussis vaccine.

REFERENCES

1 Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci U S A 2018;115:12896–901.
Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age. Available: https://www.who.int/vaccine_safety/topics/dtp/en/ (Accessed April 2020).